Cancer-Specific Mortality, Cure Fraction, and Noncancer Causes of Death Among Diffuse Large B-Cell Lymphoma Patients in the Immunochemotherapy Era

Cancer - United States
doi 10.1002/cncr.30739
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Immunochemoradiotherapy or Immunochemotherapy Only in Patients With Extranonal Diffuse Large B-Cell Lymphoma of Stomach

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Prognostic Modeling in Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy: Where Do We Go From Here?

Cancer
Cancer ResearchOncology
2017English

Antiviral Therapy and Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) With Hepatitis C (Hcv)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Diffuse Large B-Cell Lymphoma

2020English

The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

Evaluation of Treatment Patterns and Survival Among Patients With Diffuse Large B-Cell Lymphoma in the USA

Future Oncology
MedicineCancer ResearchOncology
2019English

B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Seminars in Hematology
Hematology
2015English

A Multicentre Study of Primary Breast Diffuse Large B-Cell Lymphoma in the Rituximab Era

British Journal of Haematology
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy